Insulin degludec/insulin aspart

Insulin degludec/insulin aspart
Combination of
Insulin degludec	Long-acting human insulin analog
Insulin aspart	Fast-acting human insulin analog
Clinical data
Trade names	Ryzodeg
AHFS/Drugs.com	Professional Drug Facts
License data	EU EMA: by INN;
Pregnancy; category	AU: B3; ;
Routes of; administration	Subcutaneous injection
ATC code	A10AD06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; for injection EU: Rx-only ;
Identifiers
CAS Number	1392491-77-8;
KEGG	D10570;

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.^[3] It contains insulin degludec and insulin aspart.^[3] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.^[3]

The most frequently reported side effect is hypoglycemia (low blood glucose levels).^[3]

It was approved for medical use in the European Union in January 2013,^[3] and in Australia in November 2017.^[2]

Medical uses[]

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.^[3]

Insulin degludec and insulin aspart are slightly different from human insulin.^[3] The differences mean that insulin degludec is absorbed more slowly by the body.^[3] This means it has a long duration of action.^[3] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.^[3]

References[]

^ "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
^ ^a ^b ^c "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

External links[]

"Insulin aspart mixture with insulin degludec". Drug Information Portal. U.S. National Library of Medicine.
Australian Public Assessment Report for insulin degludec (rys)/insulin aspart (rys) (PDF) (Report). Therapeutic Goods Administration (TGA).

This article about an endocrine, nutritional, or metabolic disease is a stub. You can help Wikipedia by .

[Drugs.com_pregnancy-1] "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.

[Ryzodeg_FlexTouch_and_Penfill_AU_PI-2] "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.

[Ryzodeg_EPAR-3] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]

[3]